CLCS — Cell Source, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1569340 ·
Last close
$0.37
Market Cap
$25.14M
52W High
$2.25
52W Low
$0.25
ADV30
1,191
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 0 | 0 | -998,587 | -1,481,851 | 292,446 | 1,240 | 20,428,481 |
| Sep 2024 | 0 | 0 | -831,625 | -1,417,141 | 264,660 | 22,992 | 19,205,216 |
| Jun 2024 | 0 | 0 | -1,193,679 | -1,488,788 | 429,767 | 90,549 | 17,749,268 |
| Mar 2024 | 0 | 0 | -1,138,129 | -1,275,406 | 82,589 | 23 | 16,836,732 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-748,326
Investing CF
—
Financing CF
$799,965
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-46,180,030
Inventory
—
Receivables
$50,000
ST Investments
—
EBIT TTM
$-197,198
Pretax Income TTM
$-331,307
Interest Exp TTM
$134,109
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 0 | -3,840,244 | -4,512,642 | 286,500 | 18,824,336 | -18,537,836 | -2,684,162 |
| Dec 2023 | 0 | -4,182,746 | -5,321,212 | 195,171 | 15,806,714 | -15,611,543 | -2,347,891 |
| Dec 2022 | 0 | -4,175,333 | -5,167,748 | 409,845 | 13,043,740 | -12,633,895 | -3,138,686 |
| Dec 2021 | 0 | -4,018,572 | -5,472,435 | 313,767 | 10,139,902 | -9,826,135 | -3,378,682 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-4,719,087
OpCashFlow TTM
—
Assets (Latest)
$292,446
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | $25.17M | $1.15 | — |
| BIOE | Bio Essence Corp | $25.29M | $0.47 | — |
| ABVC | ABVC BIOPHARMA, INC. | $25.36M | $0.94 | — |
| BETRF | BetterLife Pharma Inc. | $25.64M | $0.15 | — |
| ACET | Adicet Bio, Inc. | $26.03M | $2.78 | — |
News headlines (Yahoo Finance, 1h cache)
Cell Source, Inc. to Present at the LD Micro Invitational XVI
2026-05-14 20:00 · Yahoo
Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles Thi
2026-05-21 13:00 · Yahoo
Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent
2026-01-15 21:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.